Welcome to the e-CCO Library!

OP001: Gut barrier dysfunction: a primary defect in twins with Crohn’s disease predominantly caused by genetic predisposition
Year: 2018
Source: ECCO '18 Vienna
Authors:

Å.V. Keita1, C.M. Lindqvist2, Å. Öst3, C.D.L. Magana1, I. Schoultz2, J. Halfvarson4*

Created: Thursday, 21 February 2019, 9:14 AM
OP001: Whole genome sequencing and imputation in inflammatory bowel disease identifies 26 novel loci and offers therapeutically-relevant mechanistic insights
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Moutsianas L.*1, De Lange K.1, Luo Y.1,2,3, Lee J.4, Jostins L.5, Lamb C.6, Kennedy N.7, Mansfield J.8, Parkes M.4, Barrett J.1, Anderson C.1 UK Inflammatory Bowel Disease Genetics Consortium, Various, United Kingdom

Created: Wednesday, 20 February 2019, 10:36 AM
OP002: Assessment of disease activity patterns during the first 10 years after diagnosis in a population-based Crohn’s disease cohort shows a quiescent disease course for a substantial proportion of the population
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Wintjens1,2*, F. Bergey3, E. Saccenti4, S. Jeuring1,2, M. Romberg-Camps5, L. Oostenbrug5, A. Masclee1,2, D. Jonkers1,2, V. Martins dos Santos3,4, M. Pierik1,2

Created: Thursday, 21 February 2019, 9:14 AM
OP002: Epigenetic biomarkers to detect ulcerative colitis-associated neoplasia: results from phase I of the ENDCAP-C study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Iqbal T.*1, Beggs A.1, Taniere P.2, Wallis Y.3, Mehta S.4, Magill L.4, Deeks J.4, Matthews G.1, Morton D.1 EndCAP-C Consortium

Created: Wednesday, 20 February 2019, 10:36 AM
OP002: Histopathological response and remission after dual topical application of the Toll-like receptor 9 agonist DIMS0150 in patients with moderate-to-severe ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Atreya*1, A. Öst2, C. Admyre3, A. Karlsson3, T. Knittel3, J. Kowalski3, F. Scaldaferi4, M. Neurath1, C. Hawkey5

Created: Friday, 22 February 2019, 9:49 AM
OP003: Increased risk of acute arterial events in young patients with severely active inflammatory bowel disease: a nationwide French cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kirchgesner J.*1,2, Beaugerie L.1, Carrat F.3,4, Nyboe Andersen N.5, Jess T.5,6, Schwarzinger M.7,8 For the BERENICE Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
OP003: Predicting short and medium-term efficacy of the biosimilar infliximab: trough levels/do anti-drug antibodys or clinical/biochemical markers play a more important role?
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. A. Golovics*1, Z. Vegh1, M. Rutka2, K. Gecse1, A. Balint2, K. Farkas2, J. Banai3, L. Bene4, B. Gasztonyi5, T. Kristof6, L. Lakatos7, P. Miheller8, K. Palatka9, A. Patai10, A. Salamon11, T. Szamosi3, Z. Szepes12, G.T. Toth13, A. Vincze14, E. Biro15, B. Lovasz1, Z. Kurti1, F. Nagy12, T. Molnar2, P. Lakatos1

Created: Friday, 22 February 2019, 9:49 AM
OP003: Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomics
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. de Bruyn1,2*, V. Ballet3, S. Verstockt4, B. Verstockt1,3, G. Van Assche1,3, M. Ferrante1,3, K. Machiels1, S. Vermeire1,3

Created: Thursday, 21 February 2019, 9:14 AM
OP004: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric Crohns disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Stojmirovic*, R. Dobrin, R. Strauss, D. Chan, K. Li, J. Friedman

Created: Friday, 22 February 2019, 9:49 AM
OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Le Bourhis L.1, Corraliza A.2, Auzolle C.1, Ricart E.2, Hawkey C.3, Lindsay J.O.4, Clark M.3, Rogler G.5, Satsangui J.6, Haller D.7, Panes J.2, Salas A.2, Allez M.*1

Created: Wednesday, 20 February 2019, 10:36 AM
OP004: The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Schmitt1*, U. Billmeier1, J. Ulmschneider1, C. Admyre2, T. Knittel2, A. Zargari2, M.F. Neurath1, R. Atreya1

Created: Thursday, 21 February 2019, 9:14 AM
OP005: A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-tumour necrosis factor serum levels in inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Billiet*1, I. Cleynen1, M. Ferrante2, G. Van Assche2, A. Gils3, S. Vermeire2

Created: Friday, 22 February 2019, 9:49 AM
OP005: Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Danese1*, M. Neurath2, A. Kopon3, S. Zakko4, T. Simmons5, R. Fogel6, J. Maccarone7, X. Zhan7, K. Usiskin7, D. Chitkara7

Created: Thursday, 21 February 2019, 9:14 AM
OP005: The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the efficacy and safety across Italy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Guidi L.1, Fiorino G.*2, Variola A.3, Manetti N.4, Fries W.5, Rizzuto G.6, Bossa F.7, Cappello M.8, Biancone L.9, D'Incà R.10, Cantoro L.11, Castiglione F.12, Principi M.13, Annunziata M.L.14, Di Girolamo M.15, Terpin M.M.16, Cortelezzi C.C.17, Costa F.18, Amato A.19, Di Sabatino A.20, Saibeni S.21, Meucci G.22, Petruzzellis C.23, Tari R.24, Gugliemi F.W.25, Armuzzi A.26, Danese S.2, Geccherle A.3, Rogai F.4, Ventra A.5, Orlando A.6, Andriulli A.7, Scrivo B.8, Troncone E.9, Caccaro R.10, Kohn A.11, Nardone O.12, Annese V.27

Created: Wednesday, 20 February 2019, 10:36 AM
OP006: Autophagy regulates dendritic cell migration through Rac1: implications for thiopurine therapy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Wildenberg*1, P. Koelink2, K. Diederen2, A. te Velde2, V. Nuij3, M. Peppelenbosch3, M. Nobis4, O. Sansom4, C.J. van der Woude3, G. D’Haens1, G. van den Brink1

Created: Friday, 22 February 2019, 9:49 AM
OP006: Correlation of durability of response, serum trough concentrations and outcome parameters: long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Pouillon L.*1, Ferrante M.1, Van Assche G.1, Rutgeerts P.1, Noman M.1, Vande Casteele N.2, Gils A.3, Vermeire S.1

Created: Wednesday, 20 February 2019, 10:36 AM
OP006: Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn’s disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Strik1*, M. Löwenberg1, C. Ponsioen1, K. Gecse2, C. Buskens3, W. Bemelman3, G. D’Haens1

Created: Thursday, 21 February 2019, 9:14 AM
OP007: α4β7 Integrin-dependent gut homing of non-classical monocytes is essential for intestinal wound healing mediated by M2 macrophages
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Schleier1, M. Wiendl1, M.-T. Binder1, R. Atreya1, A. Watson2, C. Neufert1, I. Atreya1, M.F. Neurath1, S. Zundler1*

Created: Thursday, 21 February 2019, 9:14 AM
OP007: A multi-centre double blind randomised placebo-controlled study of the use of rectal tacrolimus in the treatment of resistant ulcerative proctitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lawrance I.C.*1,2, Baird A.1, Lightowler D.2, Radford-Smith G.3, Andrews J.M.4, Connor S.5

Created: Wednesday, 20 February 2019, 10:36 AM
OP007: Comprehensive epigenome-wide DNA methylation profiling in inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

N. Ventham*1, N. Kennedy1, A. Adams1, R. Kalla1, S. Heath2, K. O’Leary1, H. Drummond1, D. Wilson3, T. IBD-BIOM Consortium1, T. IBD-CHARACTER Consortium1, I. Gut2, E. R. Nimmo1, J. Satsangi1

Created: Friday, 22 February 2019, 9:49 AM